Neuroone Medical Technologies (NMTC) EBIT (2010 - 2026)

Neuroone Medical Technologies has disclosed EBIT across 17 years of filings, most recently posting -$2.4 million for Q1 2026.

• Quarterly EBIT rose 10.55% year-over-year to -$2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.4 million (down 11.9% YoY) and the FY2025 annual result came in at -$4.2 million, up 64.45% from the prior year.
• EBIT retreated to -$2.4 million in Q1 2026, from -$1.7 million in the prior quarter.
• Across five years, EBIT topped out at $1.7 million in Q4 2024 and bottomed at -$3.5 million in Q2 2023.
• The 5-year median for EBIT is -$2.8 million (2022), against an average of -$2.3 million.
• Year-over-year, EBIT surged 150.47% in 2024 and plunged 199.77% in 2025.
• Neuroone Medical Technologies' EBIT stood at -$1.8 million in 2022, then plunged by 90.01% to -$3.4 million in 2023, then surged by 150.47% to $1.7 million in 2024, then sank by 199.77% to -$1.7 million in 2025, then plunged by 40.41% to -$2.4 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$2.4 million, -$1.7 million, and -$1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.